Seminars in Oncology
Volume 34, Issue 6 , Pages 498-508 , December 2007

Surgery and Sentinel Lymph Node Biopsy

  • Mark B. Faries

      Affiliations

    • Corresponding Author InformationAddress correspondence to Mark B. Faries, MD, John Wayne Cancer Institute, 2200 Santa Monica Blvd, Santa Monica, CA 90404.
    • ,
  • Donald L. Morton

References 

  1. McLeod G, Davis N, Sober A. A history of melanoma from Hunter to Clark. In:  Balch C,  Houghton A,  Sober A, et al. editor. Cutaneous Melanoma. (ed 4). St. Louis, MO: Quality Medical Publishing; 2003;p. 1–11
  2. Olsen G. The malignant melanoma of the skin (New theories based on a study of 500 cases). Acta Chir Scand Suppl. 1966;365:1–222
  3. Wong CK. A study of melanocytes in the normal skin surrounding malignant melanomata. Dermatologica. 1970;141:215–225
  4. Cochran AJ. Studies of the melanocytes of the epidermis adjacent to tumors. J Invest Dermatol. 1971;57:38–43
  5. Veronesi U, Cascinelli N. Narrow excision (1-cm margin) (A safe procedure for thin cutaneous melanoma). Arch Surg. 1991;126:438–441
  6. Balch CM, Soong SJ, Smith T, et al. Long-term results of a prospective surgical trial comparing 2 cm v 4 cm excision margins for 740 patients with 1-4 mm melanomas. Ann Surg Oncol. 2001;8:101–108
  7. Thomas JM, Newton-Bishop J, A’Hern R, et al. Excision margins in high-risk malignant melanoma. N Engl J Med. 2004;350:757–766
  8. Cohn-Cedermark G, Rutqvist LE, Andersson R, et al. Long term results of a randomized study by the Swedish Melanoma Study Group on 2-cm versus 5-cm resection margins for patients with cutaneous melanoma with a tumor thickness of 0.8-2.0 mm. Cancer. 2000;89:1495–1501
  9. Khayat D, Rixe O, Martin G, et al. Surgical margins in cutaneous melanoma (2 cm versus 5 cm for lesions measuring less than 2.1-mm thick). Cancer. 2003;97:1941–1946
  10. Balch CM, Urist MM, Karakousis CP, et al. Efficacy of 2-cm surgical margins for intermediate-thickness melanomas (1 to 4 mm) (Results of a multi-institutional randomized surgical trial). Ann Surg. 1993;218:262–267
  11. Ringborg U, Brahme EM, Drewiecki K. Ranomized trial of a resection margin of 2 cm versus 4 cm for cutaneous malignant melanoma with a tumor thickness of more than 2 mm. Vancouver, BC, Canada: World Congress on Melanoma; 2005;September 6-10
  12. Haigh PI, DiFronzo LA, McCready DR. Optimal excision margins for primary cutaneous melanoma: A systematic review and meta-analysis. Can J Surg. 2003;46:419–426
  13. Posther KE, Selim MA, Mosca PJ, et al. Histopathologic characteristics, recurrence patterns, and survival of 129 patients with desmoplastic melanoma. Ann Surg Oncol. 2006;13:728–739
  14. Balch C, Soong S, Ross M, et al. Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0-4.0 mm). Ann Surg Oncol. 2000;7:87–97
  15. Thompson JF, Scolyer RA, Uren RF. Surgical management of primary cutaneous melanoma: Excision margins and the role of sentinel lymph node examination. Surg Oncol Clin N Am. 2006;15:301–318
  16. Gould EA, Winship T, Philbin PH, et al. Observations on a “sentinel node” in cancer of the parotid. Cancer. 1960;13:77–78
  17. Cabanas R. An approach for the treatment of penile carcinoma. Cancer. 1977;39:456–466
  18. Holmes E, Moseley H, Morton D, et al. A rational approach to the surgical management of melanoma. Ann Surg. 1977;186:481–490
  19. Fee HJ, Robinson DS, Sample WF, et al. The determination of lymph shed by colloidal gold scanning in patients with malignant melanoma: A preliminary study. Surgery. 1978;84:626–632
  20. Wong J, Cagle L, Morton D. Lymphatic drainage of skin to a sentinel lymph node in a feline model. Ann Surg. 1991;214:637–641
  21. Morton D, Cagle L, Wong J. Intraoperative lymphatic mapping and selective lymphadenectomy: Technical details of a new procedure for clinical stage I melanoma. 1990;Presented at the 42nd Annual Meeting of the Society of Surgical Oncology, Washington, DC, May 20–22
  22. Morton D, Wen D, Wong J, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg. 1992;127:392–399
  23. Alex JC, Krag DN. Gamma-probe guided localization of lymph nodes. Surg Oncol. 1993;2:137–143
  24. Essner R, Foshag L, Morton D. Intraoperative radiolymphoscintigraphy: A useful adjunct to intraoperative lymphatic mapping and selective lymphadenectomy in patients with clinical stage I melanoma. Houston, TX: Society of Surgical Oncology Annual Meeting; 1994;March 17-20
  25. Glass EC, Essner R, Morton DL. Kinetics of three lymphoscintigraphic agents in patients with cutaneous melanoma. J Nucl Med. 1998;39:1185–1190
  26. Uren RF, Thompson JF, Howman-Giles R, et al. The role of lymphoscintigraphy in the detection of lymph node drainage in melanoma. Surg Oncol Clin N Am. 2006;15:285–300
  27. Morton DL, Thompson JF, Essner R, et al. Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: A multicenter trial (Multicenter Selective Lymphadenectomy Trial Group). Ann Surg. 1999;230:453–463
  28. Wong SL, Kattan MW, McMasters KM, et al. A nomogram that predicts the presence of sentinel node metastasis in melanoma with better discrimination than the American Joint Committee on Cancer staging system. Ann Surg Oncol. 2005;12:282–288
  29. Rousseau DL Jr, Ross MI, Johnson MM, et al: Revised American Joint Committee on Cancer staging criteria accurately predict sentinel lymph node positivity in clinically node-negative melanoma patients. Ann Surg Oncol 10:569-574, 203
  30. Morton D, Hoon D, Cochran A, et al. Lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: Therapeutic utility and implications of nodal microanatomy and molecular staging for improving the accuracy of detection of nodal micrometastases. Ann Surg. 2003;238:538–549
  31. Gershenwald JE, Mansfield PF, Lee JE, et al. Role for lymphatic mapping and sentinel lymph node biopsy in patients with thick (> or = 4 mm) primary melanoma. Ann Surg Oncol. 2000;7:160–165
  32. Ranieri JM, Wagner JD, Wenck S, et al. The prognostic importance of sentinel lymph node biopsy in thin melanoma. Ann Surg Oncol. 2006;13:927–932
  33. Agnese DM, Abdessalam SF, Burak WE, et al. Cost-effectiveness of sentinel lymph node biopsy in thin melanomas. Surgery. 2003;134:542–547
  34. Bleicher RJ, Essner R, Foshag LJ, et al. Role of sentinel lymphadenectomy in thin invasive cutaneous melanomas. J Clin Oncol. 2003;21:1326–1331
  35. Bedrosian I, Faries MB, Guerry DT, et al. Incidence of sentinel node metastasis in patients with thin primary melanoma (< or = 1 mm) with vertical growth phase. Ann Surg Oncol. 2000;7:262–267
  36. Stitzenberg KB, Groben PA, Stern SL, et al. Indications for lymphatic mapping and sentinel lymphadenectomy in patients with thin melanoma (Breslow thickness < or =1.0 mm). Ann Surg Oncol. 2004;11:900–906
  37. Hershko DD, Robb BW, Lowy AM, et al. Sentinel lymph node biopsy in thin melanoma patients. J Surg Oncol. 2006;93:279–285
  38. Olah J, Gyulai R, Korom I, et al. Tumour regression predicts higher risk of sentinel node involvement in thin cutaneous melanomas. Br J Dermatol. 2003;149:662–663
  39. Wong SL, Brady MS, Busam KJ, et al. Results of sentinel lymph node biopsy in patients with thin melanoma. Ann Surg Oncol. 2006;13:302–309
  40. Vaquerano J, Kraybill WG, Driscoll DL, et al. American Joint Committee on Cancer clinical stage as a selection criterion for sentinel lymph node biopsy in thin melanoma. Ann Surg Oncol. 2006;13:198–204
  41. Puleo CA, Messina JL, Riker AI, et al. Sentinel node biopsy for thin melanomas: Which patients should be considered?. Cancer Control. 2005;12:230–235
  42. Koskivuo I, Suominen E, Niinikoski J, et al. Sentinel node metastasectomy in thin <or=1-mm melanoma. Langenbecks Arch Surg. 2005;390:403–407
  43. Kesmodel SB, Karakousis GC, Botbyl JD, et al. Mitotic rate as a predictor of sentinel lymph node positivity in patients with thin melanomas. Ann Surg Oncol. 2005;12:449–458
  44. Jacobs IA, Chang CK, DasGupta TK, et al. Role of sentinel lymph node biopsy in patients with thin (<1 mm) primary melanoma. Ann Surg Oncol. 2003;10:558–561
  45. Lowe JB, Hurst E, Moley JF, et al. Sentinel lymph node biopsy in patients with thin melanoma. Arch Dermatol. 2003;139:617–621
  46. Oliveira Filho RS, Ferreira LM, Biasi LJ, et al. Vertical growth phase and positive sentinel node in thin melanoma. Braz J Med Biol Res. 2003;36:347–350
  47. Woods JE, Soule EH, Creagan ET. Metastasis and death in patients with thin melanomas (less than 0.76 mm). Ann Surg. 1983;198:63–64
  48. Corsetti RL, Allen HM, Wanebo HJ. Thin < or = 1 mm level III and IV melanomas are higher risk lesions for regional failure and warrant sentinel lymph node biopsy. Ann Surg Oncol. 2000;7:456–460
  49. Karakousis GC, Gimotty PA, Botbyl JD, et al. Predictors of regional nodal disease in patients with thin melanomas. Ann Surg Oncol. 2006;13:533–541
  50. Kalady MF, White RR, Johnson JL, et al. Thin melanomas: Predictive lethal characteristics from a 30-year clinical experience. Ann Surg. 2003;238:528–535
  51. Nahabedian MY, Tufaro AP, Manson PN. Sentinel lymph node biopsy for the T1 (thin) melanoma: Is it necessary?. Ann Plast Surg. 2003;50:601–606
  52. Massi D, Franchi A, Borgognoni L, et al. Thin cutaneous malignant melanomas (< or =1.5 mm): Identification of risk factors indicative of progression. Cancer. 1999;85:1067–1076
  53. Schmid-Wendtner MH, Baumert J, Eberle J, et al. Disease progression in patients with thin cutaneous melanomas (tumour thickness < or = 0.75 mm): Clinical and epidemiological data from the Tumour Center Munich 1977-98. Br J Dermatol. 2003;149:788–793
  54. McKinnon JG, Yu XQ, McCarthy WH, et al. Prognosis for patients with thin cutaneous melanoma: long-term survival data from New South Wales Central Cancer Registry and the Sydney Melanoma Unit. Cancer. 2003;98:1223–1231
  55. Naruns PL, Nizze JA, Cochran AJ, et al. Recurrence potential of thin primary melanomas. Cancer. 1986;57:545–548
  56. Balch C, Buzaid A, Soong S, et al. Final version of the American Joint Committee on Cancer Staging System for Cutaneous Melanoma. J Clin Oncol. 2001;19:3635–3648
  57. Faries MB, Essner R, Foshag L, et al: Lymph flow decreases with age and correlates with non-sentinel node metastasis and poor survival in stage III melanoma. Proc Am Assoc Cancer Res 47:2006 (abstr 4766)
  58. Su LD, Fullen DR, Lowe L, et al. Desmoplastic and neurotropic melanoma. Cancer. 2004;100:598–604
  59. Gyorki DE, Busam K, Panageas K, et al. Sentinel lymph node biopsy for patients with cutaneous desmoplastic melanoma. Ann Surg Oncol. 2003;10:403–407
  60. Pawlik TM, Ross MI, Prieto VG, et al. Assessment of the role of sentinel lymph node biopsy for primary cutaneous desmoplastic melanoma. Cancer. 2006;106:900–906
  61. Hawkins WG, Busam KJ, Ben-Porat L, et al. Desmoplastic melanoma: a pathologically and clinically distinct form of cutaneous melanoma. Ann Surg Oncol. 2005;12:207–213
  62. Thompson JF, Uren RF. Teaching points on lymphatic mapping for melanoma from the Sydney Melanoma Unit. Semin Oncol. 2004;31:349–356
  63. Essner R. The role of lymphoscintigraphy and sentinel node mapping in assessing patient risk in melanoma. Semin Oncol. 1997;24(suppl 4):S8–S10
  64. McMasters KM, Chao C, Wong SL, et al. Interval sentinel lymph nodes in melanoma. Arch Surg. 2002;137:543–547
  65. Stradling B, Aranha G, Gabram S. Adverse skin lesions after methylene blue injections for sentinel lymph node localization. Am J Surg. 2002;184:350–352
  66. McMasters K, Reintgen D, Ross M, et al. Sentinel lymph node biopsy for melanoma: How many radioactive nodes should be removed?. Ann Surg Oncol. 2001;8:192–197
  67. Forbes RC, Pitchford C, Simpson JF, et al. Selective use of intraoperative touch prep analysis of sentinel nodes in breast cancer. Am Surg. 2005;71:955–960
  68. Kane JM, Edge SB, Winston JS, et al. Intraoperative pathologic evaluation of a breast cancer sentinel lymph node biopsy as a determinant for synchronous axillary lymph node dissection. Ann Surg Oncol. 2001;8:361–367
  69. Rubio IT, Korourian S, Cowan C, et al. Use of touch preps for intraoperative diagnosis of sentinel lymph node metastases in breast cancer. Ann Surg Oncol. 1998;5:689–694
  70. Creager AJ, Shiver SA, Shen P, et al. Intraoperative evaluation of sentinel lymph nodes for metastatic melanoma by imprint cytology. Cancer. 2002;94:3016–3022
  71. Shidham VB, Chang CC, Komorowski R. MCW melanoma cocktail for the evaluation of micrometastases in sentinel lymph nodes of cutaneous melanoma. Expert Rev Mol Diagn. 2005;5:281–290
  72. Morton D, Cochran A, Thompson J, et al. Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-1, an international multicenter trial. Ann Surg. 2005;242:302–311
  73. Wrightson WR, Wong SL, Edwards MJ, et al. Complications associated with sentinel lymph node biopsy for melanoma. Ann Surg Oncol. 2003;10:676–680
  74. Estourgie SH, Nieweg OE, Kroon BB. High incidence of in-transit metastases after sentinel node biopsy in patients with melanoma. Br J Surg. 2004;91:1370–1371
  75. Thomas JM, Clark MA. Selective lymphadenectomy in sentinel node-positive patients may increase the risk of local/in-transit recurrence in malignant melanoma. Eur J Surg Oncol. 2004;30:686–691
  76. Pawlik TM, Ross MI, Thompson JF, et al. The risk of in-transit melanoma metastasis depends on tumor biology and not the surgical approach to regional lymph nodes. J Clin Oncol. 2005;23:4588–4590
  77. van Poll D, Thompson JF, Colman MH, et al. A sentinel node biopsy does not increase the incidence of in-transit metastasis in patients with primary cutaneous melanoma. Ann Surg Oncol. 2005;12:597–608
  78. Kang JC, Wanek LA, Essner R, et al. Sentinel lymphadenectomy does not increase the incidence of in-transit metastases in primary melanoma. J Clin Oncol. 2005;23:4764–4770
  79. Essner R, Conforti A, Kelley MC, et al. Efficacy of lymphatic mapping, sentinel lymphadenectomy, and selective complete lymph node dissection as a therapeutic procedure for early-stage melanoma. Ann Surg Oncol. 1999;6:442–449
  80. Gershenwald JE, Colome MI, Lee JE, et al. Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma. J Clin Oncol. 1998;16:2253–2260
  81. Morton DL, Thompson JF, Cochran AJ, et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med. 2006;355:1307–1317
  82. Lee JH, Essner R, Torisu-Itakura H, et al. Factors predictive of tumor-positive nonsentinel lymph nodes after tumor-positive sentinel lymph node dissection for melanoma. J Clin Oncol. 2004;22:3677–3684
  83. Sabel MS, Griffith K, Sondak VK, et al. Predictors of nonsentinel lymph node positivity in patients with a positive sentinel node for melanoma. J Am Coll Surg. 2005;201:37–47
  84. Reeves ME, Delgado R, Busam KJ, et al. Prediction of nonsentinel lymph node status in melanoma. Ann Surg Oncol. 2003;10:27–31
  85. Wagner JD, Davidson D, Coleman JJ, et al. Lymph node tumor volumes in patients undergoing sentinel lymph node biopsy for cutaneous melanoma. Ann Surg Oncol. 1999;6:398–404
  86. Cochran AJ, Wen DR, Huang RR, et al. Prediction of metastatic melanoma in nonsentinel nodes and clinical outcome based on the primary melanoma and the sentinel node. Mod Pathol. 2004;17:747–755
  87. Wallace AM, Hoh CK, Vera DR, et al. Lymphoseek: A molecular radiopharmaceutical for sentinel node detection. Ann Surg Oncol. 2003;10:531–538
  88. Scoggins CR, Ross MI, Reintgen DS, et al. Prospective multi-institutional study of reverse transcriptase polymerase chain reaction for molecular staging of melanoma. J Clin Oncol. 2006;24:2849–2857
  89. Takeuchi H, Morton DL, Kuo C, et al. Prognostic significance of molecular upstaging of paraffin-embedded sentinel lymph nodes in melanoma patients. J Clin Oncol. 2004;22:2671–2680
  90. Cochran AJ, Huang RR, Lee J, et al. Tumour-induced immune modulation of sentinel lymph nodes. Nat Rev Immunol. 2006;6:659–670
  91. Gajewski TF, Meng Y, Harlin H. Immune suppression in the tumor microenvironment. J Immunother. 2006;29:233–240
  92. Eisengart CA, Mestre JR, Naama HA, et al. Prostaglandins regulate melanoma-induced cytokine production in macrophages. Cell Immunol. 2000;204:143–149
  93. Lee JH, Torisu-Itakara H, Cochran AJ, et al. Quantitative analysis of melanoma-induced cytokine-mediated immunosuppression in melanoma sentinel nodes. Clin Cancer Res. 2005;11:107–112
  94. Wen DR, Hoon DS, Chang C, et al. Variations in lymphokine generation by individual lymph nodes draining human malignant tumors. Cancer Immunol Immunother. 1989;30:277–282
  95. Cochran AJ, Wen DR, Farzad Z, et al. Immunosuppression by melanoma cells as a factor in the generation of metastatic disease. Anticancer Res. 1989;9:859–864
  96. Miyasaka M, Tanaka T. Lymphocyte trafficking across high endothelial venules: Dogmas and enigmas. Nat Rev Immunol. 2004;4:360–370
  97. Cochran AJ, Morton DL, Stern S, et al. Sentinel lymph nodes show profound downregulation of antigen-presenting cells of the paracortex: Implications for tumor biology and treatment. Mod Pathol. 2001;14:604–608
  98. Morton D, Ollila D, Hsueh E, et al. Cytoreductive surgery and adjuvant immunotherapy: A new management paradigm for metastatic melanoma. CA Cancer J Clin. 1999;49:101–116
  99. Ollila DW. Complete metastasectomy in patients with stage IV metastatic melanoma. Lancet Oncol. 2006;7:919–924
  100. Allen PJ, Coit DG. The surgical management of metastatic melanoma. Ann Surg Oncol. 2002;9:762–770
  101. Ollila D, Morton D. Surgical resection as the treatment of choice for melanoma metastatic to the lung. Chest Surg Clin N Am. 1998;8:183–196
  102. Faries MB, Bleicher RJ, Ye X, et al. Lymphatic mapping and sentinel lymphadenectomy for primary and metastatic pulmonary malignant neoplasms. Arch Surg. 2004;139:870–876
  103. Pawlik T, Zorzi D, Abdalla E, et al. Hepatic resection for metastatic melanoma: distinct patterns of recurrence and prognosis for ocular versus cutaneous disease. Ann Surg Oncol. 2006;13:712–720
  104. Wood T, DiFronzo A, Rose M, et al. Does complete resection of melanoma metastatic to solid intraabdominal organs improve survival?. Ann Surg Oncol. 2001;8:658–662
  105. Ollila D, Essner R, Wanek L, et al. Surgical resection for melanoma metastatic to the gastrointestinal tract. Arch Surg. 1996;131:975–979
  106. Morton D, Mozzillo N, Thompson J, et al. An international, randomized, double-blind, phase 3 study of the specific active immunotherapy agent, Onamelatucel-L (Canvaxin), compared to placebo as post-surgical adjuvant in AJCC stage IV melanoma. Ann Surg Oncol. 2006;13(suppl):5s
  107. Bedikian AY, Millward M, Pehamberger H, et al. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: The Oblimersen Melanoma Study Group. J Clin Oncol. 2006;24:4738–4745
  108. Eton O, Legha SS, Bedikian AY, et al. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: Results from a phase III randomized trial. J Clin Oncol. 2002;20:2045–2052
  109. Giuliano A, Kirgan D, Guenther J, et al. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg. 1994;220:391–398
  110. Liptay M, Grondin S, Fry W, et al. Intraoperative sentinel lymph node mapping in non-small-cell lung cancer improves detection of micrometastases. J Clin Oncol. 2002;20:1984–1988
  111. Bilchik A, Nora D, Tollenaar R, et al. Ultrastaging of early colon cancer using lymphatic mapping and molecular analysis. Eur J Cancer. 2002;38:977–985
  112. Bilchik AJ, Giuliano A, Essner R, et al. Universal application of intraoperative lymphatic mapping and sentinel lymphadenectomy in solid neoplasms. Cancer J Sci Am. 1998;4:351–358

 Supported by Grant No. CA29605 from the National Cancer Institute and by funding from the Amyx Foundation, Inc (Boise, ID), the Wayne and Gladys Valley Foundation (Oakland, CA), and from Mr and Mrs Louis Johnson, (Stanfield, AZ).

PII: S0093-7754(07)00185-6

doi: 10.1053/j.seminoncol.2007.09.010

Seminars in Oncology
Volume 34, Issue 6 , Pages 498-508 , December 2007

Article Tools

* Image Usage & Resolution